



### TABLE OF CONTENTS

---

●	<b>Description</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.1</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.6</b>



ISSN: 2352-3042

### DESCRIPTION

---

#### About the Journal

**Genes & Diseases** is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

#### Aims and Scopes

**Genes & Diseases** publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis will be placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

### IMPACT FACTOR

---

2019: 4.803 © Clarivate Analytics Journal Citation Reports 2020

### ABSTRACTING AND INDEXING

---

PubMed Central  
Scopus  
Directory of Open Access Journals (DOAJ)  
Science Citation Index Expanded

## EDITORIAL BOARD

---

### *Editor-in-Chief*

**Tong-Chuan He**, The University of Chicago Medical Center Molecular Oncology Laboratory, Chicago, United States

**Ailong Huang**, Chongqing Medical University, Chongqing, China

### *Deputy Editor-in-Chief*

**John Wang**, Case Western Reserve University School of Medicine, Cleveland, United States

**Xiaodong Zhao**, Chongqing Medical University, Chongqing, China

### *Executive Managing Editor*

**Ping Luo**, Chongqing Medical University, Chongqing, China

### *Assistant Managing Editors*

**Qiushan Tang**, Chongqing Medical University, Chongqing, China

**Huijie Zhang**, Chongqing Medical University, Chongqing, China

### *Senior Associate Editors*

**Ronald A. Conlon**, Case Western Reserve University School of Medicine, Cleveland, United States

**Fei Li**, University of Illinois at Chicago, China

**Zhenkun Lou**, Mayo Clinic Rochester, Rochester, United States

**Gloria H. Su**, Columbia University Irving Medical Center, New York, United States

**Ni Tang**, Chongqing Medical University, Chongqing, China

**Lin Zhang**, UPMC Hillman Cancer Center Shadyside, Pittsburgh, United States

**Peter B. Zhou**, Markey Cancer Center, Lexington, United States

### *Associate Editors*

**Andreas Bikfalvi**, Angiogenesis and Cancer Microenvironment Laboratory, Talence, France

**Youquan Bu**, Chongqing Medical University, Chongqing, China

**Tao-sheng Chen**, St Jude Children's Research Hospital Department of Chemical Biology and Therapeutics, Memphis, United States

**Gerald W Dorn II**, Washington University in St Louis School of Medicine, Saint Louis, United States

**Hicham Drissi**, Emory University School of Medicine, Atlanta, United States

**Nancy Du**, Weill Cornell Medicine, New York, United States

**Nickolai Dulin**, University of Chicago Department of Medicine, Chicago, United States

**Richard Finnell**, Baylor College of Medicine, Houston, United States

**Haian Fu**, Emory University, Atlanta, United States

**Jim Hu**, The Hospital for Sick Children, Toronto, Canada

**Aishun Jin**, Chongqing Medical University, Chongqing, China

**Xi Li**, Chongqing Medical University, Chongqing, China

**Yong Li**, Cleveland Clinic Lerner Research Institute, Cleveland, United States

**Yong Liao**, Chongqing Medical University, Chongqing, China

**Jun Liu**, Mayo Clinic Hospital, Phoenix, United States

**Hua Lu**, Tulane University School of Medicine, New Orleans, United States

**Adam Marcus**, Emory University, Atlanta, United States

**Sergey Orlov**, Department of Medical Sciences of the Russian Academy of Sciences, Moskva, Russian Federation

**Xiongzong Ruan**, University College London Department of Renal Medicine, London, United Kingdom

**Jun Sun**, University of Illinois at Chicago, Chicago, United States

**Man-Sun Sy**, Case Western Reserve University, Cleveland, United States

**Gopal Thinakaran**, University of South Florida, Tampa, United States

**Ronald JA Wanders**, University of Amsterdam, Amsterdam, Netherlands

**Da-Zhi Wang**, Harvard Medical School, Boston, United States

**Andre van Wijnen**, Mayo Clinic Department of Biochemistry and Molecular Biology, Rochester, United States

**Geng-Sheng Wu**, Wayne State University, Detroit, United States

**Yaguang Xi**, LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER, New Orleans, United States

**Tingxiu Xiang**, Chongqing Medical University, Chongqing, China

**Jingwu Xie**, Indiana University School of Medicine, Indianapolis, United States

**Qingbo Xu**, King's College London James Black Centre, London, United Kingdom

**Jian Yu**, UPMC Hillman Cancer Center Shadyside, Pittsburgh, United States

**Xingxing Zang**, Yeshiva University Albert Einstein College of Medicine, Bronx, United States

**Wei Zhou**, Emory University, Atlanta, United States

### *Editorial Board Members*

**Giuseppe Altavilla**, University of Messina Department of Human Pathology in Adulthood and Childhood, Messina, Italy

**Sergey Anisimov**, Almazov National Medical Research Centre, Sankt Peterburg, Russian Federation

**Jesus Avila**, Autonomous University of Madrid Severo Ochoa Molecular Biology Centre, Madrid, Spain  
**Anita Bellail**, Indiana University School of Medicine, Indianapolis, United States  
**Marcelo Bonini**, Medical College of Wisconsin, Milwaukee, United States  
**Vittorio Calabrese**, University of Catania, Catania, Italy  
**Timothy A. Chan**, Memorial Sloan Kettering Cancer Center, New York, United States  
**Guojun Chen**, Chongqing Medical University, Chongqing, China  
**Jianjun Chen**, City of Hope Comprehensive Cancer Center Duarte, Duarte, United States  
**Shiyuan Cheng**, Northwestern University - Chicago, Illinois, United States  
**Fabrizio Chiti**, University of Florence, Firenze, Italy  
**Hueng-Sik Choi**, Chonnam National University Hormone Research Center, Gwangju, Korea, Republic of  
**Junho Chung**, Seoul National University College of Medicine, Seoul, Korea, Republic of  
**Cristian Coarfa**, Baylor College of Medicine, Houston, United States  
**Mushui Dai**, Oregon Health & Science University, Portland, United States  
**Aiko P.J De Vries**, Leiden University Medical Center Department of Nephrology, Leiden, Netherlands  
**Danny N. Dhanasekaran**, Oklahoma City University, Oklahoma City, United States  
**Zhifang Dong**, Chongqing Medical University, Chongqing, China  
**Mingqing Du**, University of Cambridge, Cambridge, United Kingdom  
**Y. Murat ELÇİN**, Ankara University and Turkish Academy of Sciences, Ankara, Turkey  
**Matthias Eckhardt**, University of Bonn, Bonn, Germany  
**Guo-Chang Fan**, University of Cincinnati, Cincinnati, United States  
**Rong Fan**, Yale School of Engineering and Applied Science, New Haven, United States  
**Zhaohui Feng**, Rutgers University New Brunswick, United States  
**Jiliang Gao**, National Institute of Allergy and Infectious Diseases, Bethesda, United States  
**Leonard Girnita**, Karolinska Institutet CCK, Stockholm, Sweden  
**Nicholas D.E. Greene**, University College London, London, United Kingdom  
**Deliang Guo**, OHIO STATE UNIVERSITY, Columbus, United States  
**Vsevolod V Gurevich**, Vanderbilt University, Nashville, United States  
**Chunhai Charlie Hao**, IU SIMON CANCER CENTER, Indianapolis, United States  
**Vasif Hasirci**, Middle East Technical University Department of Biological Sciences, Ankara, Turkey  
**Ming-Liang He**, City University of Hong Kong, Kowloon, Hong Kong  
**Xin He**, University of Chicago, Chicago, United States  
**Yu-Ying He**, UChicago Medicine, Chicago, United States  
**Wenwei Hu**, Rutgers University New Brunswick, United States  
**George Huang**, The University of Tennessee Health Science Center Center for Cancer Research, Memphis, TN, United States  
**Esmail Jabbari**, University of South Carolina, Columbia, United States  
**Hyeong-Reh Choi Kim**, Wayne State University School of Medicine, Detroit, United States  
**Lucia Languino**, Thomas Jefferson University, Philadelphia, United States  
**Irena Levitan**, University of Illinois at Chicago College of Medicine, Chicago, United States  
**Min Li**, The University of Oklahoma Health Sciences Center, Oklahoma City, United States  
**Wan-Ju Li**, University of Wisconsin Madison, Madison, United States  
**Wei Li**, The University of Tennessee Knoxville School of Information Sciences, Knoxville, United States  
**Jie Liang**, University of Illinois at Chicago Department of Bioengineering, Chicago, United States  
**Chuanju Liu**, NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, United States  
**Pentao Liu**, University of Hong Kong, Hong Kong, Hong Kong  
**Xiaoqi Liu**, Purdue University Center for Cancer Research  
**Jun Lu**, Yale University Department of Genetics, New Haven, United States  
**Avudai Maran**, Mayo Clinic College of Medicine Department of Orthopedic Surgery, Rochester, United States  
**Valentina Massa**, University of Milan, Milan, Italy  
**Kimford Jay Meador**, Stanford University School of Medicine, Stanford, United States  
**Le Min**, Brigham and Women's Hospital, Boston, United States  
**Eiji Miyoshi**, Osaka University, Osaka, Japan  
**John F Moorhead**, University College London Department of Renal Medicine, London, United Kingdom  
**Hammad Naveed**, National University of Computer and Emerging Sciences, Islamabad, Pakistan  
**Dietbert Neumann**, Maastricht University, Maastricht, Netherlands  
**Heyu Ni**, St Michael's Hospital, Toronto, Canada  
**Ming Pei**, West Virginia University Health Sciences Center, Morgantown, United States  
**Russell Kirk Pirlo**, US Naval Research Laboratory, Washington, United States  
**Karen E. Pollok**, Indiana University School of Medicine, Indianapolis, United States  
**Zhijian Qian**, University of Florida College of Medicine, Gainesville, United States  
**Nader Rahimi**, Boston University, Boston, United States  
**Brian B. Rudkin**, Stem Cell and Brain Research Institute, Bron, France  
**Roger Schneiter**, University of Fribourg, Fribourg, Switzerland  
**Hiroshi Shibuya**, Tokyo Medical and Dental University, Tokyo, Japan  
**Jinglin Song**, Chongqing Medical University, Chongqing, China  
**Massimo Stefani**, University of Florence, Firenze, Italy

**Zhongjie Sun**, University of Tennessee Health Science Center College of Medicine Memphis, Memphis, United States  
**Young-Joon Surh**, Seoul National University College of Pharmacy, Seoul, Korea, Republic of  
**Xiaodi Tan**, Northwestern University - Chicago, Illinois, United States  
**Qian Tao**, The Chinese University of Hong Kong, New Territories, Hong Kong  
**Wei Seong Toh**, National University of Singapore, Singapore  
**Ratna K. Vadlamudi**, University of Texas Health Science Center at San Antonio, San Antonio, United States  
**Donald Vander Griend**, University of Illinois at Chicago, Chicago, United States  
**Zac Varghese**, University College London Department of Renal Medicine, London, United Kingdom  
**Alexander Vorotnikov**, Nacional'nyj issledovatel'skij tehnologiceskij universitet MISiS Gornyj institut, Moskva, Russian Federation  
**Gang Wang**, Shanghai Jiao Tong University School of Medicine, Shanghai, China  
**Jing Wang**, UNIVERSITY OF NEBRASKA MEDICAL CENTER, Omaha, United States  
**Qien Wang**, OHIO STATE UNIVERSITY, Columbus, United States  
**Tian-Li Wang**, Johns Hopkins University, Baltimore, United States  
**Qiou Wei**, Markey Cancer Center, Lexington, United States  
**Erxi Wu**, Texas A&M University Kingsville, Kingsville, United States  
**Lizi Wu**, University of Florida, Gainesville, United States  
**Wen-Shu Wu**, University of Illinois at Chicago, Chicago, United States  
**Zhaohui Wu**, The University of Tennessee Health Science Center, Memphis, United States  
**Shuli Xia**, Johns Hopkins University, Baltimore, United States  
**Yin Xiao**, Queensland University of Technology Institute of Health and Biomedical Innovation, Brisbane, Australia  
**Yin Xiao**, Queensland University of Technology Institute of Health and Biomedical Innovation, Brisbane, Australia  
**Zhongjian Xie**, University of California San Francisco, San Francisco, United States  
**Wei Xu**, University of Wisconsin Madison, Madison, United States  
**Ying Xu**, The University of Georgia, Athens, United States  
**Chunhong Yan**, Augusta University Medical College of Georgia, Augusta, United States  
**Jun Yan**, University of Louisville School of Medicine, Louisville, United States  
**Peter Yun-zhi Yang**, Stanford University Yang Laboratory, Stanford, United States  
**Xiaolu Yang**, University of Pennsylvania, Philadelphia, United States  
**Kiyotsugu Yoshida**, Jikei University School of Medicine, Minato-Ku, Japan  
**Jiwang Zhang**, Loyola University Medical Center, Maywood, United States  
**Rugang Zhang**, Wistar Institute, Philadelphia, United States  
**Ruiwen Zhang**, University of Houston College of Pharmacy, Houston, United States  
**Yuanyuan Zhang**, Wake Forest University, Winston-Salem, United States  
**Zhiqian Zhang**, Peking University Health Science Centre, Beijing, China  
**Wenge Zhu**, The George Washington University, Washington, United States  
**Hui Zong**, University of Virginia, Charlottesville, United States  
**Wei-xing Zong**, Rutgers The State University of New Jersey, New Brunswick, United States

#### ***Statistics Editors***

**Dezheng Hou**, University of Chicago, Chicago, United States  
**Xiaoyan Iris Leng**, Wake Forest University, Winston-Salem, United States  
**Yinglin Xia**, University of Illinois at Chicago, Chicago, United States

#### ***Senior Advisory Board***

**Xuetao Cao**, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China  
**Jing Cheng**, Tsinghua University academician of Chinese Academy of Engineering, Beijing, China  
**Wafik S El-Deiry**, Fox Chase Cancer Center, Philadelphia, United States  
**Charis Eng**, Cleveland Clinic, Cleveland, United States  
**Daiming Fan**, Xijing Hospital, Xian, China  
**Eric Fearon**, University of Michigan, Ann Arbor, United States  
**Wei Gu**, Columbia University Institute for Cancer Genetics, New York, United States  
**Chuan He**, University of Chicago, Chicago, United States  
**Kenneth W. Kinzler**, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States  
**Lan-Juan Li**, Zhejiang University academician of Chinese Academy of Engineering, Hangzhou, China  
**Guido Marcucci**, Beckman Research Institute, Duarte, United States  
**Sanford Markowitz**, Case Western Reserve University School of Medicine, Cleveland, United States  
**Markus Müschen**, City of Hope Comprehensive Cancer Center Duarte, Duarte, United States  
**Anil Rustgi**, Herbert Irving Comprehensive Cancer Center, New York, United States  
**Xiao-Fan Wang**, Duke University, Durham, United States  
**Zheng-guo Wang**, Army Medical University, Chongqing, China  
**Anthony Wynshaw-Boris**, Case Western Reserve University and Cleveland Medical Center, Cleveland, OH, USA  
**Huangming Yang**, Third Military Medical University academician of Chinese Academy of Engineering, Chongqing, China  
**Susheng Zheng**, Zhejiang University, Hangzhou, China

**Nan-Shan Zhong**, Guangzhou Institute of Respiratory Disease, Guangzhou, China  
**Honghao Zhou**, Central South University, Hunan, China

## GUIDE FOR AUTHORS

---

### INTRODUCTION

#### *About the Journal*

**Genes & Diseases** is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

#### *Aims and Scope*

**Genes & Diseases** publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis will be placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

#### *Editorial Process*

All manuscripts received are duly acknowledged. Upon submission, the Editorial Office will check the manuscript's conformity to technical quality and author guidelines, typically within one week. Manuscripts with insufficient conformity are returned to authors for revision. Manuscripts with insufficient originality, serious scientific or experimental flaws, or lack of interest to the readership of **Genes & Diseases** will be rejected by the Editor-in-Chief and/or Deputy Editor-in-Chief without further peer review. Manuscripts deemed suitable for publication are sent to the Executive Associate Editors. The Executive Associate Editors will make initial assessment and will serve as the managing editor, who in turn will appoint 2-3 editorial board members and/or external referees to complete peer reviews within 4 weeks. Based on the recommendations and comments made by peer reviewers, the Executive Associate Editor will make a formal recommendation to the Editor-in-Chief and/or Deputy Editor-in-Chief who will make the final decision within 1 week, in consultation with other editorial board members, if deemed necessary. The comments and recommendations (acceptance/rejection/ minor revision/ major revision in manuscript) received from reviewers are conveyed to the corresponding author. If necessary, the author is required to provide a point by point response to reviewers' comments and submit a revised manuscript. This process will be repeated till reviewers and editors are satisfied with the revised manuscript.

Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author is expected to return the corrected proofs within 48 hours. The whole process of submission of the manuscript, final decision, sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as 'Ahead of Print' immediately upon acceptance.

During submission, the contributor is requested to provide names of at least three qualified reviewers who have had experience in the subject of the submitted manuscript. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor.

#### *Contact Details for Submission*

Paper should be submitted through the **Genes & Diseases** online submission system, <https://ees.elsevier.com/gendis/>. For questions on the submission and reviewing process, please contact the Editorial Office at: [editor@genesndiseases.org](mailto:editor@genesndiseases.org); telephone +86-023-6848 5014.

### BEFORE YOU BEGIN

#### *Declaration of interest*

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the

manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### **Author contributions**

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. [More details and an example](#)

### **Authorship Statement**

The corresponding author is responsible for ensuring that all appropriate contributors are listed as authors and that all authors have agreed to the manuscript's content and its submission to **Genes & Diseases**. In any case where we become aware of an authorship dispute, authorship must be approved in writing by all of the parties. Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided in following categories, as applicable: concept and design, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review.

### **External Reviewers**

Please submit the names, institutional affiliations, and e-mail addresses of at least 3 potential external reviewers as well as a brief description of their expertise relevant to your manuscript. Suggested reviewers should be individuals qualified to evaluate the work you have submitted. The reviewers suggested may not be current, recent or extensive collaborators of yours, and must not be involved in the preparation of the manuscript. Reviewers must not be members of the same institution as the authors. Editorial Board members of **Genes & Diseases** should not be named as suggested reviewers.

Please note that the editor retains the sole right to decide whether or not the suggested reviewers are used. Failure to provide appropriate reviewer suggestions may result in your manuscript being returned to you without being reviewed.

Authors may request exclusion of certain reviewers if competing interests are anticipated. However, no more than 3 such names should be given. Entire groups or institutions cannot be specified for exclusion.

## **Ethical Approval**

For manuscripts reporting studies involving human subjects, statements identifying the committee approving the studies and confirming that informed consent was obtained from all subjects must appear in the Experimental Procedures section. All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. In the manuscript, a statement identifying the committee approving the experiments and confirming that all experiments conform to the relevant regulatory standards must be included in the Experimental Procedures section. The editors reserve the right to seek comments from reviewers or additional information from authors on any cases in which concerns arise. For more information on ethics in publishing and ethical guidelines for journal publication see <https://www.elsevier.com/publishingethics> and <https://www.elsevier.com/journal-authors/ethics>

## **Report of Clinical Trials**

All randomized controlled trials submitted for publication should include a complete Consolidated Standards of Reporting Trials (CONSORT) flow chart (available at <http://www.consort-statement.org>). This Journal has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) that requires, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) do not require registration. Further information can be found at <http://www.icmje.org>.

## **Identification of Patients in Descriptions, Photographs and Pedigrees**

A signed statement of informed consent to publish (in print and online) patient descriptions, photographs and pedigrees should be obtained from all subjects (parents or legal guardians for minors) who can be identified (including by the subjects themselves) in such written descriptions, photographs or pedigrees. Such persons should be shown the manuscript before its submission. Omitting data or making data less specific to de-identify patients is acceptable, but altering or falsifying any such data is not acceptable.

## **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

## **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

## **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

## **Changes to Authorship**

*Before the accepted manuscript is published in an online issue: requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (email, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until the authorship has been agreed upon. After the accepted manuscript is published in an online issue: any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.*

## **Language (Usage and Editing Services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<https://service.elsevier.com>) for more information.

## **Supporting Documents**

The following documents may be included:

- Conflict of Interest Statement.
- Copyright Transfer Agreement.
- Authorship Statement - All the authors' signatures must be included.
- External Reviewer Suggestions. You may use the form that follows this guide for authors. AND, where applicable.
- Ethics Statement. Articles covering human or animal experiments must be accompanied by a letter of approval from the relevant review committee or authorities.
- Consolidated Standards of Reporting Trials (CONSORT) flow chart for randomized controlled trials submitted for publication.
- Articles where human subjects can be identified in descriptions, photographs or pedigrees must be accompanied by a signed statement of informed consent to publish (in print and online) the descriptions, photographs and pedigrees from each subject who can be identified.
- Where material has been reproduced from other copyrighted sources, the letter(s) of permission from the copyright holder(s) to use the copyrighted sources must be supplied.

## **Open access**

Please visit our [Open Access page](#) for more information.

### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **PEER REVIEW**

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. For more information on the types of peer review, please visit: <https://www.elsevier.com/reviewers/peer-review>.

### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each

individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

#### *LaTeX*

You are recommended to use the Elsevier article class [elsarticle.cls](#) to prepare your manuscript and [BibTeX](#) to generate your bibliography.

Our [LaTeX site](#) has detailed submission instructions, templates and other information.

### **Cover Letter**

Submissions should be accompanied by a one-page cover letter from the corresponding author including full postal address, telephone number, and e-mail address. This letter should contain a brief explanation of the conceptual advance provided by the findings and the significance of the findings to a broad readership.

The cover letter should state clearly that 1) the reported work, in whole or in part, has not been under consideration for publication by any other primary scientific journals; and 2) all authors have read and concurred with the content of the manuscript.

### **Types of Articles**

Contributions falling into the following categories will be considered for publication: full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch. Please ensure that you select the appropriate article type from the list of options when making your submission.

#### *Full Length Article*

These may be randomized trials, intervention studies, studies of screening and diagnostic tests, laboratory and animal studies, cohort studies, cost-effectiveness analyses, case-control studies, and surveys with high response rates, which represent new and significant contributions to the field. Section headings should be: Abstract, Introduction, Material and Methods, Results, Discussion, Acknowledgments and Appendix (if applicable), and References. The Introduction should provide a brief background to the subject of the paper, explain the importance of the study, and state a precise study question or purpose. The Material and Methods section should describe the study design and methods (including the study setting and dates, patients/ participants with inclusion and exclusion criteria, or data sources and how these were selected for the study, patient samples or animal specimens used, explain the laboratory methods followed), and state the statistical procedures employed in the research. The Results section should comprise the study results presented in a logical sequence, supplemented by tables and/or figures. Take care that the text does not repeat data that are presented in tables and/or figures but only emphasize and summarize the essential features of any interventions, the main outcome measures, and the main results. The Discussion section should be used to emphasize the new and important aspects of the study, placing the results in context with published literature, the implications of the findings, and the conclusions that follow from the study results. Typical length: no more than 6000 words, 40-80 references.

#### *Review Article*

Review Article in ***Genes & Diseases*** are solicited and commissioned by the Editor-in-Chief and subject to peer review. The reviews provide an insightful overview of the recent advances in a particular field or area in experimental and translational medical research interesting to the specialist readership. Authors wishing to submit an unsolicited Review are encouraged to contact the editorial office prior to submission. Review articles are limited to 6,000 words, not counting an abstract of 200 words or fewer, as well as the figure legends and the references. It may not exceed a total of 4 tables/ figures.

#### *Short Communication*

Short manuscripts documenting high impact experimental results will be considered for publication as this category. Short manuscripts submitted for consideration are subject to the same rigorous peer review as for Original Articles. Short Communication may not exceed 2,000 words of text not counting the abstract, figure legends, and references; abstracts must not exceed 150 words and should be presented as a single paragraph with no subheadings. Only 4 figures/tables and 30 references may be included. The format of a Short Communication follows that of a Full Length Article, but the Results and Discussion are included in a single section.

### *Correspondence*

Should a reader have constructive comments or criticisms relevant to a paper published in **Genes & Diseases**, it may be accepted for publication in the form of Correspondence after a fast-track editorial review. The Correspondence may not exceed a word limit of 1000, with no more than 10 references. The Correspondence may be published together with the response from the authors of the original paper(s) under discussion. The items of correspondence may be edited by the editor prior to the publication

### *Perspectives*

Perspectives are short, commissioned scholarly reviews and discussions of the primary research article(s) that are too technical for a Commentary but do not meet the criteria for a Review because of the narrow scope. The highlighted research article(s) may appear in the same or recent issue of **Genes & Diseases**, or in other major journals. Perspectives offer a point of view on a topic of current interest. They can be speculative and creative, and are meant to stimulate thought on a topic of interest to our readership. They are short, thoughtful, and to the point. They are not intended as comprehensive reviews of the literature. The text should not exceed 1,500 words, including up to two figures/tables. References are limited to 20. Perspectives authors must provide a competing financial interests statement before publication. Perspectives are usually peer reviewed.

### *Commentary*

As a flexible format, Commentaries are short, opinion articles commissioned by the Editors. The main criteria are that they should be of immediate interest to a broad readership and should be written in an accessible, non-technical style. In some cases, Commentaries accompany a primary research article in **Genes & Diseases** to highlight an exceptional advance or to discuss a controversy in the field. They may also focus on article(s) of exceptional significance that are published elsewhere. Commentaries do not normally contain primary research data. Their length is usually limited to 1,000 words and may include one figure or table. References are limited to 10. Commentary authors must provide a competing financial interests statement before publication. Commentaries may be peer reviewed at the editor's discretion.

### *Views on News*

Views on News are commissioned by the Editors only. They may be linked to articles in **Genes & Diseases**, or they may focus on article(s) of exceptional significance that are published elsewhere. Their length is usually limited to 800 words. References are limited to 10. Views on News are not peer reviewed. Authors must provide a competing financial interests statement before publication.

### *Research Watch*

Research Watch is a format for short commissioned summaries of recent publications of exceptional and broad significance in major life science and biomedical journals. The text should not exceed 500 words with no more than 5 references. Research Watch summaries are not peer reviewed.

## **Article structure**

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

## Appendices

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

## Abstract and Keywords

Abstracts should be no more than 250 words in length. Abstracts for Full Length Articles should be unstructured with a concise description of relevant background, appropriate materials and methods used to obtain the results, and major findings and conclusions. Abstracts for Review Articles and Short Communication should be unstructured. Abbreviations and reference citations should be avoided. Below an abstract, at least 5 relevant keywords should also be provided in alphabetical order.

## Statistical Requirements

Statistical analysis is essential for all research papers except case reports. Use correct nomenclature of statistical methods (e.g., two sample  $t$  test, not unpaired  $t$  test). Descriptive statistics should follow the scales used in data description. Inferential statistics are important for interpreting results and should be described in detail. All  $p$  values should be expressed to 2 digits to the right of the decimal point, unless  $p < 0.01$ , in which case the  $p$  value should be expressed to 3 digits to the right of the decimal point. The smallest  $p$  value that should be expressed is  $p < 0.001$ , since additional zeros do not convey useful information; the largest  $p$  value that should be expressed is  $p > 0.99$ .

## Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

## Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

## Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Nomenclature and Units**

Follow internationally accepted rules and conventions: use the international system of units (SI) . If other quantities are mentioned, give their equivalent in SI. Authors wishing to present a table of nomenclature should do so on the second page of their manuscript.

#### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

#### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

### **Tables**

Tables should supplement, not duplicate, the text. They should have a concise table heading, be self-explanatory, and numbered consecutively in the order of their citation in the text. Information requiring explanatory footnotes should be denoted using superscripted lowercase letters in alphabetical order (a, b, c, etc.). Asterisks (\*, \*\*) are used only to indicate the probability level of tests of significance. Abbreviations used in the table must be defined and placed after the footnotes. If you include a block of data or table from another source, whether published or unpublished, you must acknowledge the original source.

### **Artwork and Media instructions**

Submitting your illustrations, figures and other artwork (such as multimedia and supplementary files) in an electronic format helps us produce your work to the best possible standards, ensuring accuracy, clarity and a high level of detail.

A detailed guide on electronic artwork is available on our website: <https://www.elsevier.com/author-schemas/artwork-and-media-instructions>. You are urged to visit this site; some excerpts from the detailed information are given here.

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.  
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

*Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. [Further information on the preparation of electronic artwork.](#)

*Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**References**

Indicate references by (consecutive) superscript Arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. **Genes & Diseases** is currently using the JOURNAL OF AMERICAN MEDICAL ASSOCIATION (JAMA) reference style. For further detail and examples, please refer to the AMA Manual of Style, A Guide for Authors and Editors, Ninth Edition, ISBN 0-683-40206-4, copies of which may be ordered from Lippincott Williams & Wilkins (<http://www.lww.com/index.html>).

List: number the references in the list in the order in which they appear in the text.

Examples:

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun. 2000; 163: 51-59.

Reference to a book:

2. Strunk W Jr, White EB. The Elements of Style. 3rd ed. New York, NY: Macmillan; 1979.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, eds. Introduction to the Electronic Age. New York, NY: E-Publishing Inc; 1999:281-304.

*Submission Checklist*

Only complete manuscript submissions will be considered for publication.

*Complete submission must include:*

- Cover Letter for manuscript submission
- Authorship Statement signed by all authors
- Signed Conflict of Interest disclosure statement
- Signed Copyright Transfer Agreement
- External Reviewer Suggestions.

AND, where applicable

- Letter of approval from review committee for use of human samples in research and human experiments
- Letter of approval from relevant authority for use of animals in experiments
- CONSORT flow chart for randomized controlled trial
- Signed consent to publish (online) from human subjects who can be identified in your manuscript
- Letter(s) of permission from copyright holder(s) to use copyrighted sources in your Manuscript

*In the actual article, ensure that the following information is provided:*

- Title page
- Article title
- Name(s) and affiliation(s) of author(s)
- Corresponding author details (name, e-mail address, full postal address, telephone and fax numbers)
- Abstract: unstructured for Full Length Article; unstructured for Review Article and Short Communication within 300 words
- At least 5 relevant keywords in alphabetical order
- Main text
- References in the correct format, cited in numerical order, and all references in the List are cited in the Text/Tables/Figures, and vice versa

AND, where applicable

- Acknowledgments
- All tables (including title, description, footnotes).
- All figure captions
- Electronic picture files of all figures; resolution of 300 dpi for halftone images, 500 dpi for combination art (halftone + line art), and 1000 dpi for line art

### **Further considerations**

Manuscript has been "spell-checked" and "grammar-checked"

- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced in color on the Web (free of charge) and in black-and white in print
- If only color on the Web is required, black and white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <https://service.elsevier.com> .

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software](#).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/genes-and-diseases>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee of 600 USD is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

## **AFTER ACCEPTANCE**

### **Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will be notified and receive a link to the published version of the open access article on [ScienceDirect](#). This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#).

### **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>